Condition: Hematological Patients · Newly Diagnosed Multiple Myeloma · Chemotherapy · Sponsor: Centre Hospitalier Universitaire de Saint Etienne
The association between multiple myeloma (MM) and venous thromboembolism (VTE) is well known. Indeed, the incidence of VTE is increased in patients with newly diagnosed MM and in patients treated by immunomodulatory drugs in combination with glucocorticoids. Moreover, the clinical outcome of MM is supposed to be correlated to the risk of thrombosis. At the biological level, a number of hemostasis abnormalities participate in increasing VTE incidence. Yet, data on predictive biomarkers linked to VTE are limited.
This description comes directly from the study's public registry record.
Emilie Chalayer, MD · 04 77 91 70 00 · emilie.chalayer@chu-st-etienne.fr
Elisabeth Daguenet, PhD · elisabeth.daguenet@icloire.fr
Always discuss trial participation with your own doctor first.
| Hospices Civils de Lyon | Lyon, France | Recruiting |
| CHU de Saint-Etienne | Saint-Etienne, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05259553